

Zioptan[®] (tafluprost) – First-time authorized brand alternative

- On November 18, 2022, [Prasco launched](#) an authorized brand alternative (ABA) of Akorn's [Zioptan \(tafluprost\)](#) ophthalmic solution.
- Zioptan is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.